What BPC-157 is

BPC-157 stands for Body Protection Compound 157. It is a synthetic pentadecapeptide, meaning a chain of 15 amino acids assembled in a specific sequence. That sequence was identified in a protein found naturally in human gastric juice. The "body protection compound" name comes from the original research framing around the gastric source material, which was being studied for its apparent protective properties on gut tissue.

Because BPC-157 is synthetic and its sequence is derived from a naturally occurring protein rather than being the protein itself, it is sometimes described in research as a "stable gastric pentadecapeptide." That stability in an acidic environment is pharmacologically notable: most peptides break down rapidly when exposed to gastric acid, which is why so many peptides under research are studied via injection rather than oral administration. BPC-157 retains activity in animal models under both routes, which is part of why it has attracted research attention. Whether that oral stability translates into meaningful systemic exposure in humans has not been established.

The compound does not exist as a naturally occurring peptide in the way that endogenous signaling peptides like GLP-1 or GHRH do. It was synthesized, assigned a number in a research series, and studied for effects across several tissue systems, primarily in rodent models.

Regulatory status

BPC-157 is not FDA-approved. It was flagged in a 2023 safety review.

BPC-157 has never received FDA approval for any human indication. It is not a withdrawn drug with a prior approval history; it has no approval history at all in the United States.

In 2023, the FDA conducted a bulk-substance safety review covering a list of peptides commonly used in compounded drug products. BPC-157 was included on the list of substances the FDA determined raise significant safety concerns for use in compounded preparations. This finding means that licensed compounding pharmacies operating under the federal 503A and 503B frameworks face additional regulatory scrutiny when using BPC-157 as a bulk ingredient. It does not mean the FDA found a specific documented injury, but it does mean the agency concluded the existing evidence base is insufficient to support safe use in compounded human drugs.

Research-labeled BPC-157 sold without a prescription occupies a distinct category from compounded pharmaceuticals, but it is not approved for human use either. The regulatory landscape around research peptides is actively evolving, and the 2023 review represents a meaningful change in the regulatory treatment of this specific compound.

How BPC-157 is discussed and marketed

Online discussion of BPC-157 centers almost entirely on healing and recovery: injured tendons, gut issues, and general tissue repair. Here is how the most common framing maps to the actual evidence, area by area.

Area 1

Tendon and ligament healing

This is where the animal evidence is strongest. Multiple rodent studies have demonstrated accelerated healing in severed or damaged tendons following BPC-157 administration. Researchers have observed increased collagen synthesis and fibroblast activity in treated animals. Whether these effects replicate in humans at any dose has not been tested in controlled trials.

Preclinical only
Area 2

Gut and gastrointestinal healing

Given that the compound originates from research into gastric juice proteins, the GI evidence base has received consistent attention. Animal studies have documented protective effects against gut lesions, NSAID-induced gastric damage, and inflammatory bowel-like conditions. This is among the more replicated findings in the preclinical literature, though human trial data remains absent.

Preclinical only
Area 3

Anti-inflammatory effects

BPC-157 appears to interact with the nitric oxide system in animal models, which is one proposed mechanism for its anti-inflammatory observations. Anti-inflammatory effects have been reported across several tissue types in rodent studies. The mechanistic picture is not fully mapped, and the clinical significance of these findings in humans is unknown.

Preclinical / mechanistic
Area 4

Muscle and bone repair

Some rodent studies have extended the healing framing to muscle tissue and bone injury models, with positive findings reported. This sits at the further edge of the preclinical evidence base. Marketing often presents these findings alongside the tendon data as though they represent a unified clinical picture. They do not; each tissue type requires its own human trials to establish anything.

Preclinical / preliminary

A word on dosing: research literature in rodent studies has used a range of doses, commonly reported in micrograms per kilogram of body weight, with many studies falling in the 1–10 mcg/kg range. These figures appear in the published literature and are sometimes referenced in online discussion. They are not medical advice, they are not validated for human use, and they are not a protocol. Animal-to-human dose translation for peptides involves body surface area corrections and pharmacokinetic variables that have not been studied for BPC-157 in humans. This is informational context about what the research literature contains, not a recommendation of any kind.

How to evaluate a vendor selling BPC-157

The 2023 FDA bulk-substance review makes the vendor evaluation question more pointed for BPC-157 than for many other research peptides. Anyone selling it as a research compound is operating in a space where the primary regulatory body has raised formal safety concerns about the compound's use in human preparations. That context should inform how carefully you review what a vendor provides.

Vendor evaluation checklist

  • Third-party COA from an accredited lab: The certificate of analysis should come from a laboratory that is independent of the vendor and carries ISO 17025 accreditation or equivalent. The lab name, accreditation number, and contact should be independently verifiable. A COA hosted on the vendor's own website with no verifiable lab origin is not adequate documentation.
  • Batch-level traceability: The COA must match the specific batch number on the product you are purchasing. An undated or generic COA that is not tied to a particular production batch provides limited assurance about the compound in the vial you receive. Ask for batch-specific documentation if it is not already provided.
  • Identity and purity testing methods: Look for HPLC purity data (above 98% is the general benchmark) combined with mass spectrometry or amino acid analysis confirming the peptide's sequence identity. Purity confirmed by a single method alone is less reliable than multi-method confirmation.
  • Claims review: A vendor making treatment, healing, or outcome claims about BPC-157 is marketing outside the legal scope of a research compound. Given the FDA's 2023 findings, strong therapeutic claims represent a meaningful compliance signal. Claims strength is inversely related to regulatory rigor in this space.
  • Research-only labeling: Legitimate research vendors label their products for research use only and do not offer medical guidance, dosing protocols, or administration instructions. Vendors that provide these alongside the product are operating outside the research compound framework.
  • Business transparency: Reputable vendors provide verifiable contact information, business addresses, and a clear process for batch verification inquiries. Anonymous storefronts with no traceable business identity are a quality and accountability risk.

Affiliate disclosure: The link below is a paid affiliate relationship. We earn a commission if you purchase through it at no extra cost to you. This relationship did not influence our evaluation of BPC-157 or the vendor criteria above. See our full disclosure policy.

Looking for a vendor that meets these criteria?

We reviewed vendors against the checklist above. The link below goes to a vendor whose COA documentation, batch traceability practices, and research-only labeling we found consistent with the standards described in this article. We have not independently tested the product and this is not a clinical recommendation.

View vendor COA documentation Affiliate link

BPC-157 is often discussed alongside other peptides studied for tissue repair and recovery. Two in particular appear frequently in the same context, sometimes discussed as a pair or as alternatives.

TB-500

A synthetic fragment of Thymosin Beta-4, a naturally occurring protein involved in cell migration and tissue repair. Often discussed alongside BPC-157 in recovery contexts. Evidence base is similarly preclinical, with no completed large human trials.

Read TB-500 explainer →
GHK-Cu

A copper-binding peptide found naturally in human plasma and studied for wound healing, skin remodeling, and anti-inflammatory effects. Has a broader literature base in some areas than BPC-157, including some early human skin studies. Not FDA-approved for systemic use.

Read GHK-Cu explainer →
Sermorelin

A GHRH analog studied for growth hormone axis stimulation. Different mechanism from BPC-157 but frequently purchased by a similar audience. Has a distinct regulatory history: it was once FDA-approved as Geref, then withdrawn from the US market.

Read Sermorelin explainer →

Sources

  1. 1 Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. PubMed
  2. 2 Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PubMed
  3. 3 Sikiric P, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing. Eur J Pharmacol. 2006;542(1-3):12-21. PubMed
  4. 4 Sikiric P, et al. The antidote for gastric ulcers: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 2010;17(3):312-321. PubMed
  5. 5 Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2006;36(8):683-689. PubMed
  6. 6 Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. PubMed
  7. 7 Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in healing injured tendons. Surg Oncol Rep. 2019;2:e2019.09. PubMed
  8. 8 Sikiric P, et al. BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats. Life Sci. 2017;186:184-202. PubMed
  9. 9 FDA. Bulk drug substances nominated for use in compounding under section 503B of the Federal Food, Drug, and Cosmetic Act: Category 1. FDA.gov. 2023. FDA.gov
  10. 10 FDA. Interim policy on compounding using bulk drug substances under section 503A. FDA.gov
  11. 11 Sikiric P, et al. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on skin and muscle healing. Eur J Pharmacol. 2001;430(2-3):259-266. PubMed

Frequently asked questions

What is BPC-157?
BPC-157 is a synthetic pentadecapeptide, a chain of 15 amino acids, whose sequence was identified from a protein found in human gastric juice. The name stands for Body Protection Compound 157, a designation from the research series in which it was developed. It has been studied primarily in rodent models for its effects on tissue healing, particularly in tendons, gut lining, and muscle. It is not a naturally occurring peptide in the body in the same way that endogenous signaling peptides are, but its sequence originates from a gastric source protein. BPC-157 has never been FDA-approved for any human use and is not available as an approved drug.
Is BPC-157 legal?
In the United States, BPC-157 is not FDA-approved and has no approved drug status. In 2023 the FDA conducted a bulk-substance safety review and identified BPC-157 as raising significant safety concerns for use in compounded drug products. This creates a more restricted regulatory position than many other unapproved research peptides. Research-labeled BPC-157 is sold by various vendors without a prescription, but that category is distinct from an approved or legally compounded drug. The legal landscape around research peptides is complex and actively evolving. Anyone considering purchase should consult a healthcare provider and, where relevant, a legal professional familiar with their jurisdiction.
What are BPC-157's claimed benefits?
Marketing and online community discussion around BPC-157 focuses primarily on accelerated healing of tendons and ligaments, protection and repair of the gut lining, anti-inflammatory effects, and faster recovery from injury. These claims are grounded in a substantial body of preclinical rodent research that does consistently show relevant findings in animal models. The problem is not that the animal research is weak; it is that animal results do not automatically translate to humans, and no large controlled trials in humans have been completed to test whether these findings replicate. The mechanism of action is not fully mapped. The compound's interaction with the nitric oxide system is one area of mechanistic research, but a comprehensive understanding of how it produces its effects in animal tissue does not yet exist.
How does BPC-157 compare to TB-500?
BPC-157 and TB-500 are frequently discussed together in recovery and healing contexts, and some vendors sell them as a combined preparation. They are pharmacologically distinct compounds. BPC-157 is a synthetic peptide derived from a gastric protein sequence, studied primarily for tendon, gut, and tissue healing in rodent models. TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring protein involved in cell migration, actin regulation, and tissue repair. Both are preclinical compounds with no completed large human trials. Their mechanisms of action differ, and the assumption that combining them is additive or synergistic is pharmacologically plausible but untested in controlled human research. For a full breakdown of TB-500, see the TB-500 explainer.